DEPORTE ANTIDOPING Ley 24.819 Ley de preservación de la lealtad y el juego limpio en el deporte. Creación de la Comisión Nacional Antidóping y del Registro Nacional de Sanciones Deportivas. Controles. Derogación de los arts. 25 y 26 y 26 bis de la Ley N° 20.655. El Senado y Cámara de Diputados de la Nación Argentina reunidos en Congreso, etc. sancionan con fuerza de Ley: A
Microsoft word - aridol spc.docSUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE MEDICINAL PRODUCT
Aridol, inhalation powder, hard capsule.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 capsule contains 0 mg, 5 mg, 10 mg, 20 mg or 40 mg mannitol. The delivered dose from each of the 5, 10, 20 and 40 mg capsules is approximately 3.4, 7.7, 16.5 and 34.1 mg, respectively. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL
Inhalation powder, hard capsule. The powder is white or almost white. The empty capsule is clear. The capsule containing 5 mg is half white, half clear. The capsule containing 10 mg is half yellow, half clear. The capsule containing 20 mg is half pink, half clear. Capsules containing 40 mg are half red, half clear. 4. Clinical
This medicinal product is for diagnostic use only. Aridol is indicated for identifying bronchial hyperresponsiveness in subjects with a baseline FEV1 of 70% or more of the predicted value. Posology and method of administration
The capsules are supplied in kit form containing sufficient number of capsules to complete
one maximum dose challenge, and an inhaler (Osmohaler).
The airway response to Aridol is measured using the forced expiratory volume in one second
Prior to the challenge, spirometry should be performed and the reproducibility of the baseline
The patient should be seated comfortably and encouraged to maintain good posture to assist
the effective delivery of Aridol to the lungs. The test should proceed as follows:
1. Apply a nose clip. The patient should be directed to breathe through the mouth. 2. Insert the 0 mg capsule into the inhalation device. Puncture the capsule by depressing the buttons on the sides of the device carefully, and once only (a second puncture may shatter the capsules). 3. The patient should exhale completely, before inhaling from the device in a controlled 4. At the end of the deep inspiration, start a 60 second timer. The patient should hold his/her breath for 5 seconds and exhale through the mouth before removal of the nose clip. 5. At the end of the 60 seconds, measure the FEV1 at least in duplicate to obtain two reproducible measurements. The highest reading becomes baseline FEV1. The target FEV1 is calculated by multiplying the baseline FEV1 by 0.85. 6. Insert the 5 mg capsule into the inhalation device, and proceed as above. 7. Repeat steps 1 - 5 following the dose steps in the table below until the patient has a positive response or 635 mg have been administered. DOSE STEPS FOR ARIDOL CHALLENGE
A positive response is achieved when the patient experiences either of the following: 15% fall in FEV1 from baseline (0 mg dose) or 10% incremental fall in FEV1 between doses. Examples of positive tests: 1. FEV1 fall following dose step 2: 3% FEV1 fall following dose step 3: 8% FEV1 fall following dose step 4: 16% - as the total fall is 16% (≥15%), the test is positive. FEV1 fall following dose step 3: 14% - although the total fall is <15%, the incremental fall is 11% (≥10%) and the test is positive. Points to remember: 1. There should be minimal delay between FEV1 measurement and the next dose so that the osmotic effect in the airway is cumulative. 2. At least 2 acceptable FEV1 measures should be obtained after each dose. More than 2 measurements may be required, for example in the case of variability between readings or improper manoeuvres during measurement (such as the occurrence of cough). 3. The 80 and 160 mg doses are administered in multiples of 40 mg capsules (i.e., 2 x 40 mg and 4 x 40 mg, respectively). There is no interval between administering multiple capsules for these doses. One capsule should be followed immediately by the next until the total dose has been inhaled. 4. After inhalation of each dose, the capsule should be checked to ensure it is empty. A second inhalation from the same capsule may be required if the dose has not been entirely dispersed from the capsule. Most patients recover spontaneously after the challenge test, however those with a positive challenge or who experience aggravation of asthma should receive a standard dose of a beta2 agonist to expedite recovery. Those with a negative challenge may also receive a standard dose of a beta2 agonist to expedite recovery. Following administration of a beta2 agonist, FEV1 usually returns to baseline within 10 - 20 minutes. Patients should be monitored until their FEV1 has returned to within 5% of baseline levels. Children and adolescents (under 18 years of age) The Aridol test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements (see section 5.1). There is limited information on the use of Aridol in patients 6 - 18 years of age therefore Aridol is not recommended in this population.
Known hypersensitivity to mannitol or to any of the capsule ingredients. Aridol should not be given to patients with severe airflow limitation (FEV1 <50% predicted or <1.0 l) or conditions that may be compromised by induced bronchospasm or repeated blowing manoeuvres. These include: aortic or cerebral aneurysm, uncontrolled hypertension, myocardial infarction or a cerebral vascular accident in the previous six months. Special warnings and precautions for use
Aridol is to be administered by inhalation only. Inhaled mannitol causes bronchoconstriction.
The Aridol inhalation test should only be conducted in suitable laboratories/clinics under the
supervision of an experienced physician and by a physician or another health professional
appropriately trained to perform bronchial provocation tests and to manage acute
bronchospasm. The responsible physician, appropriately trained to treat acute bronchospasm,
including appropriate use of resuscitation equipment, must be close enough to respond
quickly to an emergency. A stethoscope, sphygmomanometer, and pulse oximeter should be available. Patients should not be left unattended during the procedure once the administration of Aridol has begun. Medications to treat severe bronchospasm must be present in the testing area. They include adrenaline for subcutaneous injection, and salbutamol or other beta agonists in metered-dose inhalers. Oxygen must be available. A small-volume nebuliser should be readily available for the administration of bronchodilators. General precautions when conducting spirometry and bronchial provocation testing should be observed, including using caution in patients with the following: ventilatory impairment (baseline FEV1 of less than 70% of predicted normal values or an absolute value of 1.5 l or less in adults), spirometry induced bronchoconstriction, haemoptysis of unknown origin, pneumothorax, recent abdominal or thoracic surgery, recent intraocular surgery, unstable angina, inability to perform spirometry of acceptable quality or upper or lower respiratory tract infection in the previous 2 weeks. If a patient has spirometry induced asthma or the FEV1 fall is greater than 10% at continued administration after the 0 mg capsule, a standard dose of bronchodilator should be given and the Aridol challenge discontinued. Exercise: Vigorous exercise should be fully avoided on the day of the test, as this may affect test results. Smoking: Since smoking may affect test results it is recommended that patients refrain from smoking for at least 6 hours prior to testing. The Aridol test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements. There is limited information on the use of Aridol in patients 6 - 18 years of age therefore Aridol is not recommended in this population. The effects of repeat Aridol testing within a short period of time have not been investigated therefore careful consideration should be given to repeat use of Aridol. Interaction with other medicinal products and other forms of interaction
Regular use of inhaled corticosteroids reduces the airway sensitivity to Aridol and in many
individuals, complete inhibition of the airway response occurs.
The following medicines should be withheld before conducting an Aridol test as they may
affect the results:
Recommended periods for withholding medicines before the Aridol test are listed below.
6 - 8 hours
INHALED NON-STEROIDAL ANTI-INFLAMMATORY AGENTS e.g.
sodium cromoglycate, nedocromil sodium
SHORT-ACTING BETA2 AGONISTS eg salbutamol, terbutaline
INHALED CORTICOSTEROIDS e.g. beclomethasone dipropionate;
budesonide; fluticasone propionate
LONG-ACTING BETA2 AGONISTS e.g. salmeterol; formoterol
INHALED CORTICOSTEROIDS PLUS LONG-ACTING BETA2
AGONISTS eg fluticasone and salmeterol; budesonide and formoterol
ANTIHISTAMINES eg cetirizine, fexofenadine and loratadine
LEUKOTRIENE-RECEPTOR ANTAGONISTS e.g. montelukast sodium
Food: Ingestion of significant quantities of coffee, tea, cola drinks, chocolate or other food
containing caffeine may decrease bronchial responsiveness and should be totally avoided on
the day of the test.
There are no data for D-mannitol on treatment of pregnant women. Animal studies do not indicate harmful effects on development of the embryo/foetus (see section 5.3). The effects of a possible hyperresponsiveness reaction on the mother and/or the foetus is unknown and therefore Aridol should not be given to pregnant women. Since the overall systemic exposure for inhaled D-mannitol is assumed to be very low, no effects on breast-fed babies are expected. Aridol may be used during breast-feeding. Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed,
however there are no known effects.
A positive result with Aridol may produce symptoms of bronchospasm such as chest tightness, cough or wheezing. The safety population in the Aridol pivotal study consisted of 627 subjects. Adverse events were monitored from the beginning of the challenge to a week following the challenge day. Due to the short half-life of mannitol, the causal link would be expected to diminish over this period of time. No serious adverse events were reported during the study. Most adverse events were reported to be mild and transient. Most patients experienced cough during the challenge; however, it was only occasional in the majority of these patients (83%). In the remainder, it was frequent enough to cause some delay in continuation of the challenge (16%) or discontinuation (1%). Pharyngolaryngeal pain was also a commonly reported adverse event; its occurrence may be reduced if the mouth is rinsed after the test. The most frequent adverse events (occurring in at least 1 % of patients receiving mannitol) reported in the pivotal study are listed below by organ class and absolute frequency: Nervous system disorders: Very common (≥1/10): Headache Common (≥1/100 to <1/10): Dizziness Eye disorders: Common (≥1/100 to <1/10): Eye pruritus Respiratory, thoracic and mediastinal disorders: Common (≥1/100 to <1/10): Pharyngolaryngeal pain, Cough*, Rhinorrhoea, Throat irritation, Aggravated asthma, Dyspnoea Gastrointestinal disorders: Common (≥1/100 to <1/10): Nausea, Upper abdominal pain, Diarrhoea, Vomiting Musculoskeletal and connective tissue disorders: Common (≥1/100 to <1/10): Back pain Infections and infestations: Common (≥1/100 to <1/10): Nasopharyngitis, Upper respiratory tract infection General disorders and administration site conditions: Common (≥1/100 to <1/10): Fatigue, Chest tightness * Cough was only defined as an adverse event during the challenge test if it led to 4.9 Overdose
Susceptible persons may suffer a hyperresponsiveness reaction from an overdose. The reaction can be treated with a bronchodilator. There is some experience with Aridol in clinical studies where patients experienced a 15% fall in FEV1 and inhaled a further dose (these studies used 20 - 25% as the target FEV1 fall). The maximum fall measured was 50.2%. If excessive bronchoconstriction occurs, a beta2 agonist should be given, and oxygen if necessary.
Pharmacotherapeutic group: Other Diagnostic Agents, ATC code: V04CX.
Aridol is an indirect bronchial provocation test used to measure bronchial
Published data indicate that inhaled mannitol increases the osmolarity in the airways which
results in a release of different bronchoconstriction mediators from inflammatory cells within
the airways. The mediators then act via specific receptors to cause contraction of the
bronchial smooth muscle and the airways to narrow.
The ability of the Aridol test to identify bronchial hyperresponsiveness was investigated in a
clinical study that enrolled 646 subjects (aged 6 to 83 years) of whom 466 adult subjects
(aged 18 years and over) completed the trial. Subjects underwent two challenge tests: one
with mannitol and one with hypertonic saline at two separate visits.
Following completion of the study, a respiratory physician assessed the data and categorised
the subjects as being clinically asthmatic or non-asthmatic on the basis of their medical
history, history of respiratory symptoms, medications and the results of the hypertonic saline
challenge. In adults, compared to this clinical diagnosis, the mannitol challenge had a
sensitivity of 55%, and a specificity of 98%. The positive predictive value was 99% and the
negative predictive value was 34%.
The mannitol challenge test was positive (15% fall in FEV1) in 211 adult subjects at a mean
dose of 120.2 mg. The mean maximum FEV1 fall (± SD) for the two challenges was
comparable: 21.0% (± 5.7) for mannitol and 21.3% (± 5.9) for hypertonic saline.
For the 169 adult subjects classified as asthmatic by the respiratory physician, but negative to
mannitol, 84% were taking either inhaled corticosteroids alone or in combination with a long
acting beta2 agonist. The mean % fall in FEV1 for this group was 6.3% (± 3.7). It is important
to consider current glucocorticosteroid therapy when interpreting indirect challenge test
results. In 195 adults not taking inhaled corticosteroids, compared to the clinical diagnosis,
the mannitol challenge had a sensitivity of 65% and a specificity of 98%. The positive
predictive value was 97% and the negative predictive value was 68%.
There are no pharmacokinetic data available for dry powder mannitol following inhaled administration although limited animal data on mannitol solution indicates an absorption half-life of approximately 12 - 60 minutes. Following absorption, the pharmacokinetic profile of inhaled mannitol can be expected to follow that of intravenously administered mannitol. When administered intravenously, mannitol is eliminated largely unchanged by glomerular filtration and 80% of the dose is excreted in the urine within 3 hours. The elimination half-life in adults is approximately 1 - 2 hours. In the presence of renal failure, the half-life is extended, however this is not expected to be of clinical significance. Preclinical safety data
Preclinical data reveal no special hazard for humans based on short- and long-term oral
repeat dose toxicity, genotoxicity and local tolerance studies.
Animal reproduction studies have not been carried out with inhaled mannitol. However,
studies conducted with orally administered mannitol indicated no teratogenic effects in mice
or rats, at doses of up to 1.6g/kg, or in hamsters at 1.2g/kg.
In addition, safety of the inhalation route was demonstrated by a single dose and a two week
repeat dose toxicity study in rats that revealed no toxicologically significant findings.
List of excipients
There are no excipients in the powder.
Special precautions for storage
Do not store above 25 °C.
Nature and contents of container
Capsules are packed in Aluminium/Aluminium blisters.
1 diagnostic kit consists of:
• 1 empty capsule
• 1 capsule containing 5 mg mannitol
• 1 capsule containing 10 mg mannitol
• 1 capsule containing 20 mg mannitol • 15 capsules containing 40 mg mannitol • 1 inhaler (Osmohaler) made of styrene plastics Special precautions for disposal and other handling
No special requirements
Pharmaxis UK Limited CityPoint One Ropemaker Street London EC2Y 9AW United Kingdom 8. MARKETING
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF REVISION OF THE TEXT
20. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, Marsden40. Berkowitz BA. The relationship of pharmokinetics to pharmaco-CD, Lees AJ. Preproenkephalin and preprotachykinin messengerlogical activity, morphine, methadone and naloxone. Clin Pharma-RNA expression in normal human basal ganglia and in Parkinson’sdisease. Neuroscience 1995;66:361–376. 41. Ngai SH, Berkowitz BA, Yang JC